of this controversy expire next year.—Esther Landhuis. None http://www.alzforum.org/new/detail.asp?id=3138
in Phase 2 but failed to show clinical efficacy in a Phase 3 AD trial (see ARF related news story).—Esther
wrote.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3269 Parkinson's Disease Research
controls, suggesting it could serve as a disease biomarker, Abeliovich said.—Esther Landhuis None
York Times story). The league also has a new website focusing on health and safety.—Esther Landhuis.
analysis,” Zerr said.—Esther Landhuis. None http://www.alzforum.org/new/detail.asp?id=3402 Alzheimer's
levels of inhibition.—Esther Landhuis. This is Part 2 of a three-part series. See also Part 1, Part 3.
Almost half the AD patients had non-convulsive epileptiform activity, Mucke reported.—Esther Landhuis.
full comment below).—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3509
conference story).—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3539 Alzheimer's
for a retrospective study to look for anti-GD autoantibodies in patients with idiopathic neurodegeneration.—Esther
gamma-secretase modulator (E2212) in healthy adults.—Esther Landhuis None
in the context of the hippocampus remains to be understood,” he wrote.—Esther Landhuis None
of any mGluR5 compounds being developed for AD at present.—Esther Landhuis None
Constantine Lyketsos, a principal investigator at the study’s Johns Hopkins Bayview site in Maryland.—Esther